BAYER Supplement: Diabetic Macular Edema
Arthur Cummings
Published: Sunday, September 14, 2014
Chairman’s Introduction
Prof Jean-François Korobelnik MD, chief of the Ophthalmology Department, University Hospital (CHU) Bordeaux, France, chaired Bayer Healthcare’s Satellite Symposium “DME: When Every Letter Counts” held on 12 September at the 14th EURETINA Congress in London, United Kingdom.
“Early diagnosis of diabetic macular edema (DME) is critical, and if not treated rigorously, there is a high risk of serious loss of visual function or even blindness,” said Prof Korobelnik. The good news, however, is that clinicians now have an additional tool to add to their treatment armamentarium with the recent approval
by the European Commission of Eylea® (aflibercept solution for injection) for the treatment of visual impairment due to DME.
“The results of two phase III studies were very encouraging with the majority of patients with visual impairment due to DME experiencinga significant two-line improvement in visual acuity with aflibercept solution for injection,” Prof Korobelnik said. Discussing the approved European protocol, he explained that Eylea® is recommended at 2.0mg, equivalent to 50 microlitres, with the treatment for DME initiated with one injection per month for five consecutive doses, followed by one injection every two months.
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.